Pharmaceuticals, Biotechnology and Life Sciences
Biohaven Pharmaceutical has enrolled over 880 patients in less than nine months, in its pivotal Phase 3 clinical trial of troriluzole in generalized anxiety disorder (GAD).
Biohaven Pharmaceutical started a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients with mild-to-moderate Alzheimer’s disease (AD).
Biohaven Pharmaceutical, a privately-held, clinical stage biopharmaceutical company focused neurological diseases, has completed the second tranche of its previously disclosed $80 million private financing, and has welcomed new board members, which saw one board member step down.